Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

We recently published a list of Jeff Smith’s Top 10 Activist Targets and Their Returns Compared to the S&P 500. In this ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Viking (VKTX) stock, Structure (GPCR) stock and others surge after Pfizer’s obesity drug setback. Read more here.

Pfizer discontinues development of weight-loss pill. Investors now expect it to acquire VKTX to expand in the anti-obesity ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Pfizer’s decision was based on the results from recent dose-optimization studies, which, despite meeting key pharmacokinetic ...

Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. The gold standard ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...

Shares of Structure Therapeutics Inc ADR (NASDAQ: GPCR) climbed 6.8% following the news that Pfizer Inc. (NYSE: NYSE:PFE) has ...